HAE
Income statement / Annual
Last year (2024), Haemonetics Corporation's total revenue was $1.31 B,
an increase of 12.01% from the previous year.
In 2024, Haemonetics Corporation's net income was $117.56 M.
See Haemonetics Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
03/30/2024 |
04/01/2023 |
04/02/2022 |
04/03/2021 |
03/28/2020 |
03/30/2019 |
03/31/2018 |
04/01/2017 |
04/02/2016 |
03/28/2015 |
| Operating Revenue |
$1.31 B
|
$1.17 B
|
$993.20 M
|
$870.46 M
|
$988.48 M
|
$967.58 M
|
$903.92 M
|
$886.12 M
|
$909.68 M
|
$910.37 M
|
| Cost of Revenue |
$632.52 M |
$553.56 M |
$487.69 M |
$472.63 M |
$503.97 M |
$550.04 M |
$492.02 M |
$507.62 M |
$503.80 M |
$475.96 M |
| Gross Profit |
$676.54 M |
$615.10 M |
$505.50 M |
$397.84 M |
$484.51 M |
$417.54 M |
$411.91 M |
$378.49 M |
$405.87 M |
$434.42 M |
| Gross Profit Ratio |
0.52 |
0.53 |
0.51 |
0.46 |
0.49 |
0.43 |
0.46 |
0.43 |
0.45 |
0.48 |
| Research and Development
Expenses |
$54.44 M
|
$50.13 M
|
$46.80 M
|
$32.86 M
|
$30.88 M
|
$35.71 M
|
$39.23 M
|
$37.56 M
|
$45.57 M
|
$54.19 M
|
| General & Administrative
Expenses |
$424.68 M
|
$369.48 M
|
$335.16 M
|
$271.49 M
|
$295.38 M
|
$293.78 M
|
$313.42 M
|
$299.23 M
|
$320.07 M
|
$335.19 M
|
| Selling & Marketing
Expenses |
$7.10 M
|
$7.20 M
|
$4.40 M
|
$2.70 M
|
$4.30 M
|
$4.50 M
|
$3.10 M
|
$2.50 M
|
$3.90 M
|
$4.50 M
|
| Selling, General &
Administrative Expenses |
$431.78 M
|
$376.68 M
|
$339.56 M
|
$274.19 M
|
$299.68 M
|
$298.28 M
|
$316.52 M
|
$301.73 M
|
$323.97 M
|
$339.69 M
|
| Other Expenses |
$40.45 M |
$32.26 M |
$47.41 M |
$32.83 M |
$50.60 M |
$0.00 |
$0.00 |
-$8.10 M |
$87.67 M |
$5.44 M |
| Operating Expenses |
$526.67 M |
$459.06 M |
$433.78 M |
$339.88 M |
$330.56 M |
$333.99 M |
$355.75 M |
$339.28 M |
$369.54 M |
$393.88 M |
| Cost And Expenses |
$1.14 B |
$459.06 M |
$921.47 M |
$812.50 M |
$834.53 M |
$884.03 M |
$847.77 M |
$846.90 M |
$873.34 M |
$869.83 M |
| Interest Income |
$0.00 |
$13.00 M |
$5.80 M |
$9.40 M |
$13.50 M |
$9.91 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$13.02 M |
$14.63 M |
$17.12 M |
$16.83 M |
$16.20 M |
$9.91 M |
$4.53 M |
$8.10 M |
$9.47 M |
$9.38 M |
| Depreciation &
Amortization |
$97.22 M
|
$93.31 M
|
$97.75 M
|
$84.29 M
|
$110.29 M
|
$109.42 M
|
$89.25 M
|
$89.73 M
|
$89.91 M
|
$86.05 M
|
| EBITDA |
$262.10 M
|
$249.34 M
|
$178.50 M
|
$142.25 M
|
$264.24 M
|
$192.96 M
|
$153.03 M
|
$70.35 M
|
$45.97 M
|
$125.72 M
|
| EBITDA Ratio |
0.2 |
0.21 |
0.17 |
0.16 |
0.27 |
0.2 |
0.16 |
0.15 |
0.14 |
0.04 |
| Operating Income Ratio
|
0.13
|
0.13
|
0.08
|
0.07
|
0.16
|
0.09
|
0.06
|
-0.02
|
-0.05
|
0.04
|
| Total Other
Income/Expenses Net |
-$13.02 M
|
-$14.63 M
|
-$17.12 M
|
$14.95 M
|
-$16.20 M
|
-$9.91 M
|
$3.48 M
|
-$8.10 M
|
-$97.14 M
|
-$9.38 M
|
| Income Before Tax |
$151.87 M |
$141.40 M |
$63.63 M |
$72.91 M |
$87.15 M |
$73.63 M |
$59.63 M |
-$27.48 M |
-$53.46 M |
$31.17 M |
| Income Before Tax Ratio
|
0.12
|
0.12
|
0.06
|
0.08
|
0.09
|
0.08
|
0.07
|
-0.03
|
-0.06
|
0.03
|
| Income Tax Expense |
$34.31 M |
$26.00 M |
$20.25 M |
-$6.56 M |
$10.63 M |
$18.61 M |
$14.06 M |
-$1.21 M |
$2.16 M |
$14.27 M |
| Net Income |
$117.56 M |
$115.40 M |
$43.38 M |
$79.47 M |
$76.53 M |
$55.02 M |
$45.57 M |
-$26.27 M |
-$55.62 M |
$16.90 M |
| Net Income Ratio |
0.09 |
0.1 |
0.04 |
0.09 |
0.08 |
0.06 |
0.05 |
-0.03 |
-0.06 |
0.02 |
| EPS |
2.32 |
2.27 |
0.85 |
1.57 |
1.51 |
1.07 |
0.86 |
-0.51 |
-1.09 |
0.33 |
| EPS Diluted |
2.29 |
2.24 |
0.84 |
1.55 |
1.48 |
1.04 |
0.85 |
-0.51 |
-1.09 |
0.32 |
| Weighted Average Shares
Out |
$50.71 M
|
$50.78 M
|
$51.05 M
|
$50.69 M
|
$50.69 M
|
$51.53 M
|
$52.76 M
|
$51.51 M
|
$50.91 M
|
$51.53 M
|
| Weighted Average Shares
Out Diluted |
$51.40 M
|
$51.42 M
|
$51.35 M
|
$51.29 M
|
$51.82 M
|
$52.94 M
|
$53.50 M
|
$51.52 M
|
$50.91 M
|
$52.09 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
